PCR Technologies Market - By Product (Kits & Reagents, Consumables, Instruments, Software & Services), Technique (Conventional PCR, Real-time PCR, Digital PCR, Reverse Transcription PCR, Hot-start PCR), Application, End-use – Global Forecast (2024 - 2032)

PCR Technologies Market Size

PCR Technologies Market size was valued at around USD 14.4 billion in 2023 and is estimated to grow at 8.1% CAGR from 2024 to 2032. PCR (Polymerase Chain Reaction) technologies refer to a collection of methods used to amplify, or make many copies of, a specific DNA sequence. This technique allows scientists to produce millions to billions of copies of a particular DNA segment from a very small initial sample.
 

The escalating prevalence of infectious diseases and genetic disorders underscores the growing necessity for PCR technologies. Citing the World Health Organization (WHO), genetic disorders and congenital abnormalities affect approximately 2%-5% of all live births, contributing to up to 30% of pediatric hospital admissions and around 50% of childhood fatalities in industrialized nations. Therefore, as these conditions become more prevalent, the demand for PCR-based tests is expected to rise. These tests are essential for rapidly and accurately identifying pathogens and genetic mutations, facilitating timely diagnosis, treatment, and optimal disease management.
 

Furthermore, PCR has undergone significant advancements over the years, leading to the development of faster, more sensitive, and highly efficient PCR techniques. These advancements include real-time PCR, digital PCR, and multiplex PCR, among others. Each iteration brings improvements in speed, accuracy, and the ability to detect multiple targets simultaneously, thus widening its applications in diagnostics and research.
 

PCR Technologies Market Trends

• Molecular diagnostics which is estimated to reach USD 36 billion by 2032, which utilize PCR technologies, are becoming increasingly important in healthcare for their ability to provide rapid and accurate results.
   
• Additionally, the demand for point-of-care testing (POCT) is rising due to the need for decentralized testing in remote areas, clinics, and emergency settings. PCR-based POCT devices enable rapid diagnosis, leading to better patient outcomes and improved disease management.
   
• Further, PCR technologies continue to be at the forefront of biomedical research and development. Researchers are constantly innovating to enhance PCR techniques, develop new assays, and improve the sensitivity and specificity of PCR-based tests.
   
• This ongoing R&D effort drives the adoption of PCR technologies across various fields such as clinical diagnostics, pharmaceuticals, and forensics.
   

PCR Technologies Market Analysis

Based on product, the market is divided into kits & reagents, consumables, instruments, and software & services. The kits & reagents segment of the market is forecasted to reach USD 11.6 billion by 2032.
 

• This surge is fueled by various factors, including the rising demand for accurate molecular diagnostic tests, particularly in infectious diseases and oncology. PCR kits and reagents play a crucial role in these tests, driving their demand.
   
• Additionally, the expanding applications of PCR technology in research, forensics, and pharmaceutical industries, coupled with ongoing technological advancements, contribute to market expansion.
   
• Efforts to improve accessibility and affordability, supportive regulatory environments, and increasing investments in research and development activities further stimulate the growth.
   
• Thus, these dynamics collectively create a conducive environment for the robust expansion of the PCR kits and reagents segment.
   

Based on technique, the PCR technologies market is bifurcated into conventional PCR, real-time PCR, digital PCR, reverse transcription PCR, hot-start PCR, multiplex PCR, and other techniques. The real-time PCR-based devices segment accounted for USD 4.7 billion in 2023, driven by its critical role in COVID-19 testing, which relies on real-time PCR for the accurate and sensitive detection of SARS-CoV-2.
 

• Unlike conventional PCR, real-time PCR allows for quantitative analysis of target DNA or RNA, making it essential for determining viral loads, gene expression, and genetic variations.
   
• Its widespread use in research, clinical diagnostics, pharmaceuticals, and forensics is due to its precision, sensitivity, and capability for automation, which enhances efficiency and reduces contamination risks. Additionally, the technology's multiplexing capability and expanding applications contribute to its market growth.
   

Based on application, the PCR technologies market is divided into gene expression analysis, genetic sequencing, genotyping, nucleic acid detection, nucleic acid synthesis, standard validation/ verification, diagnostic application, and other applications. The diagnostic application segment of the market is forecasted to reach USD 6.4 billion by 2032, displaying robust growth propelled by several key factors.
 

• The increasing prevalence of infectious diseases and the rise in chronic conditions like cancer and cardiovascular diseases necessitate precise and rapid diagnostic tools, for which PCR is essential due to its high sensitivity and specificity.
   
• Technological advancements, including real-time and digital PCR, enhance diagnostic capabilities, while the growing adoption of precision medicine relies on PCR for genetic analysis.
   
• Additionally, the demand for rapid diagnostics, particularly highlighted by the COVID-19 pandemic, integration with automated systems for efficiency, supportive government policies, and the expansion of point-of-care testing further propel the robust growth of this market segment.
   

Based on end-use, the PCR technologies market is bifurcated into hospitals & diagnostic centers, research & academics institutes, pharma & biotech companies, and other end-users. The hospitals & diagnostic centers segment accounted for USD 5.5 billion in 2023.
 

• Hospitals and diagnostic centers, as primary locations for medical diagnostics, heavily rely on PCR technology for its high throughput and sensitivity in detecting various infectious diseases, including COVID-19, influenza, HIV, and bacterial and fungal infections.
   
• Significant investments from both government and private sectors in healthcare infrastructure have focused on enhancing diagnostic capabilities, including the procurement and implementation of advanced PCR technology. Such financial backing ensures that hospitals and diagnostic centers are well-equipped to handle diagnostic needs efficiently.
   
• These factors collectively drive the growth of the hospitals and diagnostic centers segment in the market.
   

The growth of the PCR technologies market in the U.S., projected to reach USD 10.4 billion by 2032, is driven by increased investment in biomedical research, significantly supported by government funding initiatives and grants.
 

• Key agencies like the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA), and the Centers for Disease Control and Prevention (CDC) allocate substantial funds to research projects that rely on advanced PCR technologies.
   
• These investments facilitate advancements in genomics, infectious disease monitoring, cancer research, and public health surveillance, bolstering the demand for PCR systems across research institutions and biotech companies.
   

The PCR technologies market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK boasts a rich ecosystem of academic institutions, research organizations, and biotechnology companies at the forefront of molecular biology and biotechnology research. This research prowess translates into a strong demand for PCR technologies in academic research, drug discovery, and biotechnology applications. Collaborations between academia, industry, and government further accelerate technology development and adoption, stimulating the market growth.
   

Japan PCR technologies market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The growing demand for personalized medicine and targeted therapies underscores the importance of precise genetic analysis, fueling the adoption of PCR technologies in Japan. These technologies enable clinicians to tailor treatment strategies based on individual genetic profiles, thereby improving therapeutic outcomes and patient care.
   

The PCR technologies market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia has been investing heavily in its healthcare infrastructure in recent years, aiming to enhance its healthcare services and facilities. Therefore, as PCR is a fundamental tool in diagnostics, the increased investment in healthcare is likely to drive the demand for PCR technologies.
   

PCR Technologies Market Share

The PCR technologies sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

PCR Technologies Market Companies

Some of the eminent market participants operating in the PCR technologies industry include:

• Abbott Laboratories
• Agilent Technologies, Inc.
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Eppendorf SE
• F. Hoffmann-LA Roche Ltd.
• Illumina, Inc.
• Merck KGaA
• New England Biolabs
• Promega Corporation
• QIAGEN N.V.
• Standard Biotools Inc.
• Takara Holdings Inc.
• Thermo Fisher Scientific Inc.
   

PCR Technologies Industry News:

• In November 2023, Roche launched the LightCycler PRO System, a valuable addition to its in-vitro molecular PCR testing portfolio. This strategic move expanded Roche's market reach and reinforced its position as a leading provider of innovative solutions in molecular diagnostics.
   
• In March 2023, Bio-Rad Laboratories, Inc., announced that AOAC INTERNATIONAL and AFNOR approved the CFX Opus Deepwell Real-Time PCR System for use with Bio-Rad iQ-Check Real-Time PCR Kits. This enhanced the product capabilities of in-vitro diagnostics, thereby generating sales.
   

The PCR technologies market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Kits & reagents
• Consumables
  • PCR tubes
  • PCR microplates
  • Cap/lids
  • Other consumables
• Instruments
• Software & services

Market, By Technique

• Conventional PCR
• Real-time PCR
• Digital PCR
• Reverse transcription PCR
• Hot-start PCR
• Multiplex PCR
• Other techniques

Market, By Application

• Gene expression analysis
• Genetic sequencing
• Genotyping
• Nucleic acid detection
• Nucleic acid synthesis
• Standard validation/ verification
• Diagnostic application
• Other applications

Market, By End-use

• Hospitals & diagnostic centers
• Research & academics institutes
• Pharma & biotech companies
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa